UY31171A1 - Anhídridos y polímeros de esteres borónicos cíclicos y acíclicos, sus enantiómeros, sus sales farmacéuticamente aceptables, composiciones conteniéndolos y aplicaciones. - Google Patents

Anhídridos y polímeros de esteres borónicos cíclicos y acíclicos, sus enantiómeros, sus sales farmacéuticamente aceptables, composiciones conteniéndolos y aplicaciones.

Info

Publication number
UY31171A1
UY31171A1 UY31171A UY31171A UY31171A1 UY 31171 A1 UY31171 A1 UY 31171A1 UY 31171 A UY31171 A UY 31171A UY 31171 A UY31171 A UY 31171A UY 31171 A1 UY31171 A1 UY 31171A1
Authority
UY
Uruguay
Prior art keywords
compositions containing
enantiomers
cyclic
polymers
applications
Prior art date
Application number
UY31171A
Other languages
English (en)
Inventor
Chan Minh Ha
Xiaosong Lu
El Mehdi Keramane
Rahim Mohammad
Huchen Zhou
Rajeshwar Singh
Michael Richard Kevin Alley
Jacob J Plattner
Yong-Kang Zhang
Tsutomu Akama
James A Nieman
Rashmi Sharma
Vincent S Hernandez
Stephen J Baker
Xia Yi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40156702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31171(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of UY31171A1 publication Critical patent/UY31171A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta invención proporciona, entre otras cosas, compuestos novedosos útiles para tratar infecciones bacterianas, composiciones farmacéuticas que contienen tales compuestos, así como combinaciones de estos compuestos con al menos un agente terapéuticamente eficaz adicional.
UY31171A 2007-06-20 2008-06-20 Anhídridos y polímeros de esteres borónicos cíclicos y acíclicos, sus enantiómeros, sus sales farmacéuticamente aceptables, composiciones conteniéndolos y aplicaciones. UY31171A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94529407P 2007-06-20 2007-06-20
US4117808P 2008-03-31 2008-03-31

Publications (1)

Publication Number Publication Date
UY31171A1 true UY31171A1 (es) 2009-04-30

Family

ID=40156702

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31171A UY31171A1 (es) 2007-06-20 2008-06-20 Anhídridos y polímeros de esteres borónicos cíclicos y acíclicos, sus enantiómeros, sus sales farmacéuticamente aceptables, composiciones conteniéndolos y aplicaciones.

Country Status (29)

Country Link
US (4) US7816344B2 (es)
EP (1) EP2164331B1 (es)
JP (3) JP5530923B2 (es)
KR (3) KR20150100945A (es)
CN (2) CN104017008A (es)
AR (1) AR067105A1 (es)
AU (1) AU2008265630B2 (es)
BR (1) BRPI0813450B8 (es)
CA (1) CA2692135C (es)
CL (1) CL2008001855A1 (es)
CO (1) CO6251209A2 (es)
CR (1) CR11224A (es)
DK (1) DK2164331T3 (es)
DO (1) DOP2009000281A (es)
EA (1) EA020530B1 (es)
ES (1) ES2655299T3 (es)
IL (1) IL202379A (es)
JO (1) JO3396B1 (es)
MA (1) MA31675B1 (es)
MX (1) MX347688B (es)
MY (1) MY162692A (es)
NO (1) NO2164331T3 (es)
NZ (1) NZ582706A (es)
PE (1) PE20090840A1 (es)
SG (1) SG182219A1 (es)
TW (1) TW200911822A (es)
UY (1) UY31171A1 (es)
WO (1) WO2008157726A1 (es)
ZA (2) ZA200909003B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2540966T3 (es) 2005-02-16 2015-07-15 Anacor Pharmaceuticals, Inc. Compuestos biocidas de boronoftalida
BRPI0621279B1 (pt) 2005-12-30 2021-07-20 Anacor Pharmaceuticals, Inc Moléculas pequenas contendo boro
DK2719388T3 (da) 2006-02-16 2019-05-13 Anacor Pharmaceuticals Inc Borholdige små molekyler som antiinflammatoriske midler
US8106031B2 (en) 2006-05-02 2012-01-31 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
EP3246034A1 (en) 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
EP2285384A4 (en) * 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
WO2010027975A1 (en) 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
JP2012512262A (ja) * 2008-12-17 2012-05-31 アナコール ファーマシューティカルズ，インコーポレーテッド （ｓ）−３−アミノメチル−７−（３−ヒドロキシ−プロポキシ）−３ｈ−ベンゾ［ｃ］［１，２］オキサボロール−１−オールの多形体
US8668911B2 (en) * 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
US8343944B2 (en) * 2009-07-28 2013-01-01 Anacor Pharmaceuticals, Inc. Trisubstituted boron-containing molecules
WO2011019618A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011019612A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011019616A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
MX2012002031A (es) * 2009-08-19 2012-07-04 Anacor Pharmaceuticals Inc Moleculas pequeñas que contienen boro como agentes antiprotozoarios.
WO2011037731A1 (en) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
US8979820B2 (en) 2009-10-09 2015-03-17 Cynthia S. Bailey Method and apparatus for improving the appearance of nails affected by onychomycosis through the topical application of an aqueous solution containing boric acid and camphor or other terpenes
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060199A1 (en) * 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
WO2011116348A1 (en) 2010-03-19 2011-09-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agent
ES2710105T3 (es) * 2010-04-07 2019-04-23 Glaxosmithkline Llc Proceso para preparar benzoxaboroles
DK2613788T3 (en) * 2010-09-07 2017-08-07 Anacor Pharmaceuticals Inc BENZOXABOROLD DERIVATIVES FOR TREATMENT OF BACTERIA INFECTIONS
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
WO2013049424A1 (en) 2011-09-28 2013-04-04 Wisconsin Alumni Research Foundation Catalytic conversion of cellulose to fuels and chemicals using boronic acids
AR088668A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Moleculas pequeñas que contienen boro
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
WO2013093615A1 (en) 2011-12-22 2013-06-27 Micurx Pharmaceuticals, Inc. Tricyclic boron compounds for antimicrobial therapy
US20150080342A1 (en) * 2012-04-14 2015-03-19 Anacor Pharmaceuticals, Inc. Benzoxaborole compounds and uses thereof
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
CA2899317A1 (en) 2013-01-30 2014-08-07 Dow Agrosciences Llc Use of benzoxaboroles as volatile antimicrobial agents on meats, plants, or plant parts
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US9585396B2 (en) 2013-01-30 2017-03-07 Agrofresh Inc. Volatile applications against pathogens
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9598443B2 (en) 2013-02-01 2017-03-21 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
AU2014202928B1 (en) * 2013-06-05 2014-09-11 Agrofresh Inc. Compounds and compositions
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
LT3030519T (lt) * 2013-08-09 2022-04-11 Glaxosmithkline Intellectual Property (No. 2) Limited Tricikliniai benzoksaborolo junginiai ir jų naudojimas
EA038093B1 (ru) * 2013-12-20 2021-07-05 Глаксосмитклайн Интеллекчуал Проперти (№2) Лимитед Способ лечения заболевания, вызванного инфекцией комплекса mycobacterium tuberculosis, с использованием (s)-(3-хлор-7,8-дигидро-2h-1,6,9-триокса-9a-борабензо[cd]азулен-2-ил)метанамина или его фармацевтически приемлемой соли
MX2016010451A (es) * 2014-02-17 2016-09-22 Syngenta Participations Ag Benzoxaboroles microbicidamente activos.
CA2953881A1 (en) 2014-07-01 2016-01-07 Daiichi Sankyo Company, Limited Tricyclic benzoxaboroles as antibacterial agents
US9738664B2 (en) * 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
MA41494B1 (fr) * 2015-02-12 2020-10-28 Glaxosmithkline Ip No 2 Ltd Composés benzoxaborole substitués en position 4 et utilisations associées
BR112017021478B1 (pt) * 2015-04-09 2022-04-19 The Penn State Research Foundation Composição antifúngica sinérgica que contém benzoxaborol
CA3014757C (en) * 2015-08-06 2020-01-14 The Penn State Research Foundation Benzoxaborole-containing coating resistant to cellulose-supportable fungus
US10611780B2 (en) 2016-03-02 2020-04-07 Bill And Melinda Gates Foundation Boron-containing small molecules
US10874679B2 (en) 2016-03-02 2020-12-29 Bill & Melinda Gates Foundation Boron-containing small molecules
EP3423159A4 (en) 2016-03-02 2019-11-06 Anacor Pharmaceuticals, Inc. BORN SMALL MOLECULES
EP3426029B1 (en) 2016-03-07 2023-08-30 AgroFresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
ES2882782T3 (es) 2016-05-12 2021-12-02 Anacor Pharmaceuticals Inc Derivados de benzoxaborol amida L-valinato para el tratamiento de enfermedades parasitarias
US10961261B2 (en) 2017-03-01 2021-03-30 Anacor Pharmaceuticals, Inc. Oxaborole analogs and uses thereof
CN107090000B (zh) * 2017-04-27 2019-07-12 上海交通大学 一种苯并硼唑7位脂肪酸的衍生物及其制备与用途
EP3639005B1 (en) 2017-06-13 2024-05-22 Veterinary Diagnostics Institute, Inc. Method for extracting blood samples from dried blood spots
US20190159457A1 (en) * 2017-11-30 2019-05-30 Boragen, Inc. Combinatorial Compositions of Benzoxaboroles and Biologic Agents
BR112020010927A2 (pt) * 2017-11-30 2020-12-01 Boragen, Inc. compostos de benzoxaborol e formulações dos mesmos
JP2021534247A (ja) * 2018-08-18 2021-12-09 ボラゲン，インコーポレーテッド 置換ベンゾキサボロールの固体形態およびその組成物
AR116305A1 (es) * 2018-09-07 2021-04-21 Boragen Inc Compuestos que contienen boro y sus usos
US11058695B2 (en) * 2019-11-08 2021-07-13 Myongji University Industry And Academia Cooperation Foundation Inhibitor of carbapenem-hydrolyzing class D beta-lactamases
US20230340530A1 (en) 2020-08-31 2023-10-26 Pfizer Inc. Methods of Protecting RNA
AU2023287063A1 (en) * 2022-06-23 2024-05-30 Shanghai Micurx Pharmaceutical Co., Ltd. Prodrugs of boron compounds and their use in treating bacterial infections
CA3239096A1 (en) * 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2260336A (en) 1939-10-16 1941-10-28 Dow Chemical Co Method of preparation of organic borates
GB1396904A (en) * 1972-08-11 1975-06-11 Ici Ltd Method for the control of micro-organisms
US5962498A (en) 1986-06-11 1999-10-05 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. C. indolactam structural-types with anti-inflammatory activity
US4919934A (en) 1989-03-02 1990-04-24 Richardson-Vicks Inc. Cosmetic sticks
US5594151A (en) 1994-01-28 1997-01-14 Prolinx, Inc. Phenylboronic acid complexing reagents derived from aminosalicylic acid
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5831046A (en) 1996-08-05 1998-11-03 Prolinx, Incorporated Boronic acid-contaning nucleic acid monomers
US6306628B1 (en) 1999-08-25 2001-10-23 Ambergen, Incorporated Methods for the detection, analysis and isolation of Nascent proteins
WO2001025226A1 (en) 1999-10-05 2001-04-12 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
WO2002006316A2 (en) 2000-07-14 2002-01-24 Zycos, Inc. Alpha-msh related compounds and methods of use
US6537733B2 (en) * 2001-02-23 2003-03-25 Applied Materials, Inc. Method of depositing low dielectric constant silicon carbide layers
GB0117645D0 (en) 2001-07-19 2001-09-12 Isis Innovation Therapeutic stratergies for prevention and treatment of alzheimers disease
DE10143979A1 (de) 2001-09-07 2003-03-27 Clariant Gmbh Verfahren zur Herstellung von Bisallylboranen und nicht-aromatischen Boronsäuren
US7217701B2 (en) 2001-10-11 2007-05-15 Katsuhiko Mikoshiba Intracellular calcium concentration increase inhibitors
JP4138662B2 (ja) 2002-01-10 2008-08-27 ザ・ペンシルバニア・ステイト・リサーチ・フアウンデイシヨン アルキルジアリールボリネートおよび錯化ジアリールボロン酸を調製するための方法。
US7109354B2 (en) * 2002-05-28 2006-09-19 3-Dimensional Pharmaceuticals, Inc. Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
BRPI0411582A (pt) * 2003-06-16 2006-08-08 Anacor Pharmaceuticals Inc substáncias terapêuticas contendo boro hidroliticamente resistentes e método de uso
KR101314461B1 (ko) 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
ES2540966T3 (es) * 2005-02-16 2015-07-15 Anacor Pharmaceuticals, Inc. Compuestos biocidas de boronoftalida
BRPI0621279B1 (pt) 2005-12-30 2021-07-20 Anacor Pharmaceuticals, Inc Moléculas pequenas contendo boro
DK2719388T3 (da) * 2006-02-16 2019-05-13 Anacor Pharmaceuticals Inc Borholdige små molekyler som antiinflammatoriske midler
KR20090029797A (ko) 2006-06-12 2009-03-23 아나코르 파마슈티칼스 인코포레이티드 치주질환의 치료를 위한 화합물
US20070286822A1 (en) 2006-06-12 2007-12-13 Anacor Pharmaceuticals Inc. Compounds for the Treatment of Periodontal Disease
DE102006038471A1 (de) 2006-08-17 2008-04-10 Wala-Heilmittel Gmbh Platanencreme, Verfahren zu ihrer Herstellung und Verwendung
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
EP2285384A4 (en) * 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES

Also Published As

Publication number Publication date
ZA201104573B (en) 2014-03-26
ES2655299T3 (es) 2018-02-19
US8895534B2 (en) 2014-11-25
CN101772302A (zh) 2010-07-07
KR101685656B1 (ko) 2016-12-12
NO2164331T3 (es) 2018-04-28
CA2692135C (en) 2017-01-24
JP5530923B2 (ja) 2014-06-25
DK2164331T3 (da) 2018-01-29
KR20100051615A (ko) 2010-05-17
TW200911822A (en) 2009-03-16
CN104017008A (zh) 2014-09-03
EP2164331A4 (en) 2011-09-07
US10533021B2 (en) 2020-01-14
MX347688B (es) 2017-05-09
CA2692135A1 (en) 2008-12-24
EP2164331B1 (en) 2017-11-29
NZ582706A (en) 2012-07-27
JP2014148531A (ja) 2014-08-21
DOP2009000281A (es) 2010-07-31
US20090227541A1 (en) 2009-09-10
US20150133402A1 (en) 2015-05-14
CL2008001855A1 (es) 2009-05-29
PE20090840A1 (es) 2009-07-08
MY162692A (en) 2017-07-14
IL202379A (en) 2016-02-29
MA31675B1 (fr) 2010-09-01
JP2010530881A (ja) 2010-09-16
CO6251209A2 (es) 2011-02-21
US20180016285A1 (en) 2018-01-18
CR11224A (es) 2010-06-28
BRPI0813450B8 (pt) 2021-05-25
WO2008157726A1 (en) 2008-12-24
SG182219A1 (en) 2012-07-30
EA200901617A1 (ru) 2010-06-30
JP6570391B2 (ja) 2019-09-04
EP2164331A1 (en) 2010-03-24
IL202379A0 (en) 2010-06-30
US20100292504A1 (en) 2010-11-18
AU2008265630A1 (en) 2008-12-24
US9796735B2 (en) 2017-10-24
KR101578351B1 (ko) 2015-12-17
EA020530B1 (ru) 2014-11-28
AU2008265630B2 (en) 2013-06-20
ZA200909003B (en) 2022-03-30
KR20160049025A (ko) 2016-05-04
JO3396B1 (ar) 2019-10-20
CN101772302B (zh) 2014-05-07
JP2016040275A (ja) 2016-03-24
KR20150100945A (ko) 2015-09-02
BRPI0813450B1 (pt) 2019-05-07
BRPI0813450A2 (pt) 2014-12-30
AR067105A1 (es) 2009-09-30
US7816344B2 (en) 2010-10-19

Similar Documents

Publication Publication Date Title
UY31171A1 (es) Anhídridos y polímeros de esteres borónicos cíclicos y acíclicos, sus enantiómeros, sus sales farmacéuticamente aceptables, composiciones conteniéndolos y aplicaciones.
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2009000426A1 (es) Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas
CL2017002482A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
CL2010001641A1 (es) Compuestos derivados de heterociclos biciclicos sustituidos; composicion farmaceutica; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas e inflamatorias tales como cancer y artritis reumatoide entre otras.
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
MX2012002031A (es) Moleculas pequeñas que contienen boro como agentes antiprotozoarios.
EA201390274A1 (ru) Борсодержащие малые молекулы
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
BR112019024566A2 (pt) inibidores de pirazol magl
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
UY32937A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
SV2010003650A (es) INHIBIDORES HETEROCICLICOS DE ESTEAROIL-CoA-DESATURASA
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
CL2011000258A1 (es) Compuestos derivados de fenilamino-isonicotinamida; inhibidores de mek; composicion farmaceutica y uso para el tratamiento de enfermedades hiperproliferativas tales como cancer e inflamacion.
CL2017002451A1 (es) Compuestos heterocíclicos novedosos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas
CL2011002907A1 (es) Compuestos derivados de nitrilo; sus composiciones farmacéuticas y su uso para el tratamiento de enfermedades hiperproliferativas.
AR072425A1 (es) Uso de nifurtimox para el tratamiento de giardiasis
CL2012000393A1 (es) Compuestos octasacaridos n-acilados; composicion farmaceutica; intermediarios; utiles en el tratamiento de enfermedades tales como isquemia, angina de pecho, aterosclerosis, entre otras.